Aldeyra Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
February 18 2021 - 8:00AM
Business Wire
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today
announced that Todd C. Brady, M.D., Ph.D., President and Chief
Executive Officer, will present at the 10th Annual SVB Leerink
Global Healthcare Conference at 3:40 p.m. ET Friday, February 26,
2021.
A live webcast of the presentation will be available on the
investor relations page of the company’s corporate website at
https://ir.aldeyra.com/. After the live webcast, the event will
remain archived on the Aldeyra Therapeutics website for 90
days.
About Aldeyra Therapeutics, Inc. Aldeyra Therapeutics is
a clinical-stage biotechnology company focused on the development
of novel therapies with the potential to improve the lives of
patients with immune-mediated diseases. Two of the company’s lead
investigational compounds, reproxalap and ADX-629, target RASP
(reactive aldehyde species), which are elevated in ocular and
systemic inflammatory disease and result in cytokine release via
activation of a broad array of inflammatory factors, including
NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being
evaluated in Phase 3 clinical trials in patients with dry eye
disease and allergic conjunctivitis. The company’s clinical
pipeline also includes ADX-2191, a dihydrofolate reductase
inhibitor in Phase 3 testing for proliferative vitreoretinopathy,
and ADX-1612, a chaperome inhibitor in development for COVID-19 and
ovarian cancer. For more information, visit
https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210218005125/en/
Corporate Contact: Joshua Reed Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218 jreed@aldeyra.com
Investor & Media Contact: Scott Solomon Sharon
Merrill Associates, Inc. Tel: 617-542-5300
ALDX@investorrelations.com
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Apr 2023 to Apr 2024